301 related articles for article (PubMed ID: 26386320)
1. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
3. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.
García-Cadenas I; Rivera I; Martino R; Esquirol A; Barba P; Novelli S; Orti G; Briones J; Brunet S; Valcarcel D; Sierra J
Bone Marrow Transplant; 2017 Jan; 52(1):107-113. PubMed ID: 27595281
[TBL] [Abstract][Full Text] [Related]
4. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
5. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
6. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
[TBL] [Abstract][Full Text] [Related]
7. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
8. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.
Zhao Y; Wu H; Shi J; Luo Y; Li X; Lan J; Ni W; Lu Y; Chen L; Tan Y; Lai X; Yu J; Huang H
Am J Hematol; 2020 Sep; 95(9):1075-1084. PubMed ID: 32510625
[TBL] [Abstract][Full Text] [Related]
10. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.
Xhaard A; Rocha V; Bueno B; de Latour RP; Lenglet J; Petropoulou A; Rodriguez-Otero P; Ribaud P; Porcher R; Socié G; Robin M
Biol Blood Marrow Transplant; 2012 Mar; 18(3):406-13. PubMed ID: 21736868
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.
Dotoli GM; De Santis GC; Orellana MD; de Lima Prata K; Caruso SR; Fernandes TR; Rensi Colturato VA; Kondo AT; Hamerschlak N; Simões BP; Covas DT
Bone Marrow Transplant; 2017 Jun; 52(6):859-862. PubMed ID: 28287644
[TBL] [Abstract][Full Text] [Related]
12. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
Piñana JL; Valcárcel D; Martino R; Moreno ME; Sureda A; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1135-41. PubMed ID: 17085306
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.
Rashidi A; DeFor TE; Holtan SG; Blazar BR; Weisdorf DJ; MacMillan ML
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2297-2302. PubMed ID: 31325587
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
15. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
[TBL] [Abstract][Full Text] [Related]
16. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
17. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
